1 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 4 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow upanovimab: new trials by email Literature Review of upanovimab trials Research Report on upanovimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19 SCTA01 and SCTA01C, Placebo - COVID-19 | Phase 1 / Phase 2 | Withdrawn | Sinocelltech Ltd. | 2022-01-15 | 2022-01-27 | |
| To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 SCTA01, Placebo - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Not yet recruiting | Sinocelltech Ltd. | 690 | 2021-03-28 | 2021-03-29 |
| The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19 SCTA01, Placebo - Covid19 | Phase 2 / Phase 3 | Terminated | Sinocelltech Ltd. | 102 | 2021-03-27 | 2025-10-24 |
| The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care SCTA01, SCTA01 Placebo - Covid19 | Phase 2 / Phase 3 | Unknown | Sinocelltech Ltd. | 560 | 2021-02-25 | 2021-01-20 |
| Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects SCTA01, Placebo - Coronavirus Disease 2019(COVID-19) | Phase 1 | Completed | Sinocelltech Ltd. | 33 | 2020-07-24 | 2021-03-23 |
COVID-19 (5)
Argentina (1) · Brazil (1) · Chile (1) · China (1) · Colombia (1) · Mexico (1) · Peru (1) · United States (1)
Zhanghua Lan, PhD (2) · Xinghe Wang, MD,PhD (1)